Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
9 participants
INTERVENTIONAL
2008-03-31
2008-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of the Safety and Efficacy of AGN-214868 in Patients With Postherpetic Neuralgia
NCT01129531
Safety and Efficacy of AGN 203818 in Patients With Painful Diabetic Peripheral Neuropathy
NCT00381719
Oral LAT8881 in Neuropathic Pain
NCT03865953
Study to Assess the Efficacy, Safety, and Tolerability of ADL5747 in Participants With Postherpetic Neuralgia
NCT01058642
Efficacy and Safety of ATNC05 in Treatment of Atypical Facial Pain
NCT01920087
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
AGN201781
AGN201781 50 mg capsules three-time daily for 2 weeks
AGN201781
AGN201781 50 mg capsules three-times daily for 2 weeks
Placebo
placebo 50 mg capsules three-times daily for 2 weeks
placebo
placebo 50 mg capsules three-times daily for 2 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AGN201781
AGN201781 50 mg capsules three-times daily for 2 weeks
placebo
placebo 50 mg capsules three-times daily for 2 weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Moderate or severe pain associated with postherpetic neuralgia or post-traumatic peripheral neuralgia
Exclusion Criteria
* Any other uncontrolled diseases
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Allergan
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Director
Role: STUDY_DIRECTOR
Allergan
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
St Leonards, New South Wales, Australia
Kiel, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
201781-504
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.